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Background: Immunoglobulin G4 related disease (IgG4-RD) is a poorly understood chronic inflammatory disorder
affecting the middle-aged and elderly that can present to the otolaryngologist. We aim to summarize the current
literature regarding the manifestations and management of IgG4-RD in the head and neck.
Methods: Pubmed and EMBASE were searched using the term relevant search algorithm utilizing keywords such
as: IgG4 related disease, head and neck, orbit, salivary glands, sialadenitis, Kuttner, angiocentric eosinophilic fibrosis,
submandibular, lacrimal, thyroid, dacryoadenitis, nasal, sinus, and Mikulicz’s. Reference lists were searched for
identification of relevant studies.
Case reports, original research and review articles published in English from 1964 to 2014 whose major topic
was IgG4-RD affecting the head and neck were included. Data regarding patient demographics, presentation,
histopathology, management and treatment outcomes of IgG4-RD were extracted. Level of evidence was also
assessed and data were pooled where possible. Three independent reviewers screened eligible studies; extracted
relevant data and discrepancies were resolved by consensus, where applicable. Descriptive and comparative statistics
were performed.
Results: Fourty-three articles met our inclusion criteria. IgG4-RD most often presents as a mass lesion in the head and
neck region. Common diagnostic features include: 1) elevated serum IgG4 level, 2) marked infiltration of exocrine glands
by IgG4-positive plasma cells with fibrosis, and 3) marked improvement with corticosteroid therapy and additional
immunosuppressive therapy in corticosteroid refractory cases. Early diagnosis and involvement of rheumatology is
important in management.
Conclusions: IgG4-RD is a challenging non-surgical disease that has multiple manifestations in the head and
neck. It must be distinguished from various mimics including malignancy, systemic diseases, and infectious.
Otolaryngology-Head and Neck surgeons should be aware of this condition and its management.
Keywords: IgG4-RD, Head and neck, Systematic review, Salivary glands, Lacrimal glands, LymphandenopathyIntroduction
Immunoglobulin G4 – related disease (IgG4-RD) is a
newly described fibroinflammatory condition that often
presents as a tumefactive lesion that can affect nearly
every organ system. IgG4-RD was first recognized after a
connection between elevated serum IgG4 levels and
inflammatory mass lesions in the pancreas causing
autoimmune pancreatitis was made by Hamano et al. in
2001 [1]. An initial consensus statement regarding diag-
nosis of IgG4-RD was developed by Deshpande et al. at* Correspondence: graemem@ualberta.ca
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creativecommons.org/publicdomain/zero/1.0/the first international symposium for IgG4-RD held in
October of 2011 [2]. After the pancreas, the head and
neck region is second most common site for presenta-
tion of IgG4-RD. More, a number of historically
perplexing pseudotumor disorders have been attributed
to IgG4-RD; these include Mikulicz’s disease, Küttner’s
tumor and Reidel’s thyroiditis [3].
The exact etiology of IgG4-RD is unknown and no
known role of the IgG4 molecule itself has been identi-
fied. It is postulated that the inflammatory and fibrotic
processes that drives IgG4-RD are propagated by a com-
bination of Th2 cells and regulatory T cells (Treg cells)
[4]. This is contrary to most autoimmune disorders wheress article distributed under the terms of the Creative Commons Attribution
by/4.0) which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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sponsible for the inflammatory process [5]. Histologically,
the hallmark findings for IgG4-RD include lymphoplasma-
cytic infiltration, storiform fibrosis, obliterative phlebitis,
and mild to moderate tissue eosinophilia [6]. However, the
exact histological findings vary greatly depending on the
tissue affected and clinical presentation. Currently, the
histologic diagnosis of IgG4-RD is based primarily on
IgG4 positive to IgG containing cell ratio and the num-
ber of IgG4 positive cells per high powered field, a ratio
of IgG4 to IgG that is higher than 50 % and 30 IgG4-
positive cells per high-power field is considered to be
highly suggestive of IgG4-RD [6].Fig. 1 Flow chart of studies obtained through literature search, eligible andCurrently, the literature proposes that IgG4-RD could
be both over and under recognised [7]. This study aims
to examine the various presentations of IgG4-RD in the
head and neck, and present the management and out-
comes reported in the literature.
Material and methods
This systematic review was performed using the follow-
ing search strategy and study selection criteria.
Literature search strategy
The databases PubMed (1966-December 2014) and
Embase (1988-December 2014) were searched using anexcluded (Uploaded separately as per submission instructions)
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search terms (see Appendix A for Pubmed and Embase
search algorithms).
We included all original studies, case reports, case
series, and reviews. Relevant articles and abstracts were
selected and reviewed and the reference lists from these
sources and recent review articles were also reviewed for
additional publications.Study selection
Three independent reviewers screened the identified
articles (GBM, CCJ and PS). Relevant articles were
obtained and reviewed in full. Discrepancies were
resolved by consensus amongst the reviewers. The inclu-
sion criteria comprised of all original clinical studies,
case series and case reports of histologically confirmed
IgG4-RD in the head and neck. Histologic diagnosis of
IgG4-RD required identification of >10 IgG4 positive
plasma cells per high powered field, IgG4 + plasma cell
to IgG containing cell ratio 40 % or greater, and charac-
teristic finding of fibrosis, sclerosis and phlebitis. Articles
were excluded on the basis of biopsy information not
being from a head and neck site, insufficient histologicTable 1 Country of origin and characteristics of included articles





















Brazilinformation, inability to extract head and neck specific
information and narrative review and expert opinions.
Data extraction
The information gathered for each study included study
design, country of publication and number of patients.
Where possible, patient-specific data was extracted,
including age at presentation, duration and nature of
symptoms. Specifically, we collected data regarding head
and neck manifestations, laboratory and histologic findings
as well as specific treatments and outcome information.
Statistical analysis
Basic statistical analysis, including descriptive statistics
was performed using Excel (Version 19.0, Microsoft ®).
Results
We initially identified 1592 articles through a combin-
ation of literature search and citation review. After
reviewing abstracts, 247 articles of interest were identi-
fied. Three authors independently reviewed the articles
and 43 articles met inclusion criteria (Fig. 1). Of the 43
articles, 21 case reports and 5 large case series (greater
than 15 patients) were included (Table 1). A largeN (Articles) % N (Individual Cases) %
43 484
21 48.8 21 4.3
17 39.5 107 22.1
5 11.6 356 73.6
10 23.3 27 5.6
1 2.3 1 0.2
9 20.9 26 5.4
22 51.2 429 88.6
18 41.9 419 86.6
2 4.7 8 1.7
1 2.3 1 0.2
1 2.3 1 0.2
6 14.0 7 1.4
5 11.6 6 1.2
1 2.3 1 0.2
4 9.3 20 4.1
1 2.3 1 0.2
1 2.3 12 2.5
1 2.3 6 1.2
1 2.3 1 0.2
1 2.3 1 0.2
1 2.3 1 0.2
Table 2 Basic patient demographics
Total number of Patients 484
Average Age (years) 60.4
Percent Males 47.5 %
Table 4 Laboratory and histologic findings
Mean Values
Serum IgG4 (mg/dL) 702.9
Serum IgG (mg/dL) 2445.0
IgG4 + ve Plasma Cells / HPF 69.8
IgG4 + ve Cells / IgG Containing Cells 48.0 %
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uting 86.6 % of the total individual cases (Table 1).
Four hundred and eighty-four patients were identified
with an average patient age of 60.4 years (Table 2). Table 3
shows the proportion of patients presenting by various
sites in the head and neck. Cervical lymphadenopathy was
document in 22 cases. Many of the patients also had
involvement of other organ systems at the time of presen-
tation, including 56 patients with lymphadenopathy out-
side of the head and neck (see Table 3). All patients had
tissue biopsy from head and neck sites confirming the
diagnosis of IgG4-RD. Confirmatory laboratory investiga-
tions was included where documented. The laboratory
and histologic findings of patients indentified in the litera-
ture are summarized in Table 4.
Treatment information was available for 26.7 % of pa-
tients. Patients were treated with surgical excision, radio-
therapy, corticosteroids with or without adjunct medicalTable 3 Systemic and head and neck manifestations
Head & Neck
Manifestations
Site Subsite n %
Total presentations 730
Orbit 384 52.6
Lacrimal Gland 136 18.6
Extra Ocular Muscles 9 1.2
Optic Nerve 5 0.7
Salivary Glands 162 22.2
Submandibular Gland 107 14.7
Parotid Gland 29 4.0
Sublingual Gland 1 0.1
Minor Salivary Gland 1 0.1
Thyroid 31 4.2
Facial Skin 6 0.8













56 7.7treatment, or some combination of treatment modalities.
The distribution of patients in terms of treatment(s)
received and their outcomes are summarized in Table 5.
Treatment outcomes were known in 99 patients. Of
these, full remission was seen in 90.0 % in response to
medical treatment. Corticosteroids treatment alone
was effective for 67 patients (67.7 %) in achieving full
remission.Discussion
This is the first systematic review of IgG4-RD presenta-
tion in the head and neck. Our study demonstrates a
strong propensity for IgG4-RD to present in the head
and neck region. We included 43 articles containing 484
patients. The most common site of presentation was the
orbit, followed by the submandibular gland – with many
patients having presentations in multiple head and neck
and distant sites. Treatment information was also
collected, showing that majority of patients receiving
corticosteroids responded very well to treatment.
The vast majority of the included cases were from Asia
(429 of 484 or 88.6 %) and more specifically Japan (419
of 484 or 86.6 %). Indeed, much of the literature on
IgG4-RD originates from Japan [8]. This poses the ques-
tion of whether IgG4-RD more prevalent in the Japanese
population or simply better recognized? While IgG4-RD
was first recognized in Japan, it is increasingly recog-
nized throughout the rest of the world [7]. While cases
have been reported on every continent and in most
ethnic groups, reports from countries outside of Asia
comprise smaller case series. This highlights the emer-
ging status of IgG4-RD in the literature and likely an
increase in reporting in the future.
While systemic presentations of IgG4-RD favor males
over females with a reported ratio of 2.8-3.5:1, our study
demonstrates an almost 1 to 1 ratio of head and neck
manifestations [6, 9, 10]. Orbital involvement was most
common subsite in the head and neck and the majority
of the orbital presentations (219 cases) came from a
single study [11]. Common orbital manifestations
included periorbital swelling, eyelid swelling, and prop-
tosis. Salivary gland and lacrimal gland involvement were
very common and included submandibular, parotid
gland, and lacrimal gland enlargement, infiltration, and
formation of pseudotumours. Lymphadenopathy was a
Table 5 Treatment and progress
Treatments Received by Patients (N = 129) n %
Surgical Management Alone 15 11.6
Combined Surgical and Medical Management 4 3.1
Medical Management Alone 107 82.9
Treatment with Corticosteroidsa Alone 84 65.1
Treatment with Corticosteroids and One Additional
Immunosuppressive Agentb
16 12.4
Treatment with Corticosteroids and Multiple Additional
Immunosuppressive Agents
10 7.8
Treatment Outcomes (N = 99) n %
Full Remission with Medical Treatment 89 90.0
Full Remission with Corticosteroids Alone 67 67.7
Intolerance, Relapse with Taper, or Treatment Failure with
Corticosteroids as First Line
32 32.3
Full Remission with Addition of Single Immunosuppressive Agent to
Corticosteroids
14 14.1
Full Remission with Addition of Multiple Immunosuppressive Agents
to Corticosteroids
8 8.1
Remission Not Achieved 9 9.1
aCorticosteroids included: prednisolone, methylprednisone and triamcinolone injections
bAdditional immunosuppressive agents included: rituximab, methotrexate, azathioprine, mycophenolate mofetil, tamoxifen, 6-mercaptopurine, chlorambucil,
cyclosporine and cyclopohosphamide
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This was often associated with lymphadenopathy else-
where including the mediastinum and retroperitoneum.
More rare forms of head and neck involvement included
the thyroid gland in the form of Riedel’s Thyroiditis as
well as sinonasal and airway manifestations.
Few patients in our series received surgical excision
alone. The majority cases received some form of medical
management comprising of high-dose corticosteroids.
Patients had excellent response to medical therapy alone
with full remission rate of 90 %. A consensus statement
from 17 referral centres in Japan developed a treatment
regime of 0.6 mg/Kg prednisolone for 2 to 4 weeks with
a taper over 3 to 6 months and a low daily dose for 3 years.
Importantly, this regime was developed for treatment of
autoimmune pancreatitis, where consequences of not
treating are associated with significant morbidity and mor-
tality [12]. However, other authors advocate watchful wait-
ing with observation over a number of years as an
acceptable treatment approach [13]. Based on our results,
surgery remains most useful for obtaining histologic
diagnosis.
Strict selection criteria was used in article selection.
Histologic diagnosis was based on IgG4 + ve cells/ HPF
and the IgG4 + ve/IgG ratio. This is considered the most
rigorous definition of IgG4-RD [4, 6]. However, since
biopsy from the head and neck was one of the criteria,
there are likely many studies of IgG4-RD in the head
and neck that were excluded as biopsies were obtainedfrom other tissues. Unfortunately, there is a paucity of
high quality publications on this topic. The majority of
the information available exists in the form of case
reports and small case series, which comprise of low
level of evidence. There are also inconsistencies in
reporting key information. Many studies were excluded
due to insufficient information (152 or 74.5 %) or a lack
of basic histologic information; articles lacking IgG4+
cell/HPF or the IgG4+/IgG ratio –items critical to con-
firming the presence of IgG4-RD-- were excluded.
Conclusions
Due to the numerous potential manifestations of IgG4-RD
in the head and neck, it is crucial for otolaryngologists to
be aware of this condition. A high index of suspicious is
required particularly in the setting of patients who present
with recurrent salivary and lacrimal gland swelling,
lymphadenopathy, along with fibroinflammatory systemic
involvement. This disease process remains under recog-
nized and poorly understood. Future studies are necessary
to better understand the pathophysiology and natural his-
tory of this disease.
Appendix A: search strategy
Ovid: Embase search:
1. exp salivary gland/
2. mouth disease/ or lip disease/ or exp mouth tumor/
or exp palate disease/ or exp pharynx disease/ or
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or xerostomia/
3. head/ or exp “face, nose and sinuses”/ or exp skull/
4. “head and neck disease”/ or exp “head and neck
tumor”/
5. neck/
6. exp lacrimal apparatus/
7. exp lacrimal gland disease/
8. exp ear nose throat disease/
9. angiocentric eosinophilic fibrosis.mp.
10. (Facial or eyelid* or mouth or oral or gingival or
lip or lips or palate or palatal or tonsil* or sinuses
or sinus cavit* or salivary gland* or tongue or
otorhinolaryngologic or ear or ears or larynx or
laryngeal or nose or noses or paranasal or
pharyngeal or parathyroid or thyroid or tracheal
or sialadenitis or kuttner or submandibular or
lacrimal or thyroid or dacryoadenitis or orbit or
mikulicz*).ti,ab.
11. or/1-10
12. (immunoglobulin g4 or igg4).mp.
13. 11 and 12
14. limit 13 to english language
15. limit 14 to exclude medline journals
16. 14 not 15
17. limit 16 to (conference abstract or conference
paper or conference proceeding or “conference
review”)
18. 14 not 17
19. limit 18 to embase
Ovid: Pubmed search:
1. exp Salivary Gland Diseases/
2. exp Head/
3. Neck/
4. exp Lacrimal Apparatus Diseases/ or exp Lacrimal
Apparatus/ or exp Lacrimal Duct Obstruction/
5. angiocentric eosinophilic fibrosis.mp.
6. nose diseases/ or granuloma, lethal midline/ or
nasal obstruction/ or exp nose neoplasms/
or exp paranasal sinus diseases/
7. orbital diseases/ or exp exophthalmos/ or orbital
pseudotumor/
8. exp Frontal Sinus/ or exp Sphenoid Sinus/ or exp
Maxillary Sinus/ or exp Pyriform Sinus/ or exp
Ethmoid Sinus/
9. (Facial or eyelid* or mouth or oral or gingival
or lip or lips or palate or palatal or tonsil*
or sinuses or sinus cavit* or salivary gland*
or tongue or otorhinolaryngologic or ear or ears
or larynx or laryngeal or nose or noses or paranasal
or pharyngeal or parathyroid or thyroid or tracheal
or sialadenitis or kuttner or submandibular orlacrimal or thyroid or dacryoadenitis or orbit* or
mikulicz*).mp.
10. (immunoglobulin g4 or igg4).mp.
11. or/1-9
12. 10 and 11
13. limit 12 to english language
14. remove duplicates from 13
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